Compare Heron Therapeutics Inc (HRTX) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs New York Times Co — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while New York Times Co trades at $66.32 (market cap $10.74B). The key difference: New York Times Co is far larger — about 157.9× Heron Therapeutics Inc's market cap, and New York Times Co pays a 1.38% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and New York Times Co for 81 Days on average.
| HRTX | NYT | |
|---|---|---|
Market Cap | $68.01M | $10.74B |
Volume | 1,891,941 | 2,096,352 |
Sector | Health | Media |
52-Week High | $1.49 | $85.86 |
52-Week Low | $0.27 | $54.66 |
Typical Hold Time | 35 Days | 81 Days |
Enterprise Value | $174.75M | $10.14B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
The New York Times Company (NYT) trades at $66.60, up 2.62% today, reflecting strong momentum after three consecutive quarterly earnings beats. Revenue and net income have grown steadily from 2022 to 2025, with profit margins expanding to 12.17%. The stock shows a bullish technical signal overall, supported by positive cash flow trends and a declared quarterly dividend of $0.23 per share. However, a recent shareholder lawsuit alleging reporting bias introduces reputational risk.
Outlook remains positive given consistent earnings outperformance and a consensus price target of $84.00, implying significant upside. Key risks include the ongoing lawsuit, competitive pressures in digital media, and potential volatility from the AI copyright dispute with OpenAI. The company's solid fundamentals and analyst support suggest resilience, but investors should weigh legal and market challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
